Summary
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of YTB323. YTB323 will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (DLBCL) and in adult acute lymphoblastic leukemia (ALL).
Official Title
Phase I, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients With CLL/SLL, DLBCL and ALL
Keywords
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia, CAR-T, ibrutinib, CLL, DLBCL, ALL, BLRM, YTB323, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, YTB323 and ibrutinib, YTB323 single agent, CLL/SLL, DLBCL